Skip to main content
SpringerLink
Log in

Pharmacological interventions are of limited benefit in helping individuals to reduce their use of smokeless tobacco

  • Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

References

  1. Ebbert JO, Fagerstrom K. Pharmacological interventions for the treatment of smokeless tobacco use. CNS Drugs 2012; 26 (1): 1–10

    Article  PubMed  CAS  Google Scholar 

  2. Centers for Disease Control and Prevention. Smokeless tobacco facts [online]. Available from: http://www.cdc.gov/tobacco/data_statistics/fact_sheets/smokeless/smokeless_facts/ [Accessed 2012 May 25]

  3. Harm reduction in nicotine addiction: helping people who can’t quit. A report by the Tobacco Advisory Group of the Royal College of Physicians. London: Royal College of Physicians, 2007 Oct

  4. Substance Abuse and Mental Health Services Administration. Results from the 2009 National Survey on Drug Use and Health: volume I. Summary of national findings. Rockville (MD): U.S. Department of Health and Human Services, 2010 Sep

    Google Scholar 

  5. Swedish National Institute of Public Health. Tobacco habits [online]. Available from URL: http://www.fhi.se/en/Highlights/National-Survey-of-Public-Health/Living-habits/Tobacco-habits-/ [Accessed 2012 May 25]

  6. Boffetta P, Hecht S, Gray N, et al. Smokeless tobacco and cancer. Lancet Oncol 2008 Jul; 9 (7): 667–75

    Article  PubMed  Google Scholar 

  7. Henley SJ, Thun MJ, Connell C, et al. Two large prospective studies of mortality among men who use snuff or chewing tobacco (United States). Cancer Causes Control 2005 May; 16 (4): 347–58

    Article  PubMed  Google Scholar 

  8. Tobacco Control Research. Monograph 2. Smokeless tobacco or health: an international perspective. Bethesda (MD): National Cancer Institute, 2012 May 22

  9. Ebbert J, Montori VM, Erwin PJ, et al. Interventions for smokeless tobacco use cessation. Cochrane Database Syst Rev 2011; (2): CD004306

    PubMed  Google Scholar 

  10. Fiore MC, Jaen CR, Baker TB, et al. Clinical practice guideline: treating tobacco use and dependence 2008 update. Rockville (MD): U.S. Department of Health and Human Services, 2008 May

    Google Scholar 

  11. Fagerstrom K, Gilljam H, Metcalfe M, et al. Stopping smokeless tobacco with varenicline: randomised double blind placebo controlled trial. BMJ 2010; 341: c6549

    Article  PubMed  Google Scholar 

  12. Dale LC, Ebbert JO, Glover ED, et al. Bupropion SR for the treatment of smokeless tobacco use. Drug Alcohol Depend 2007 Sep 6; 90 (1): 56–63

    Article  PubMed  CAS  Google Scholar 

  13. Hatsukami DK, Grillo M, Boyle R, et al. Treatment of spit tobacco users with transdermal nicotine system and mint snuff. J Consult Clin Psychol 2000; 68 (2): 241–9

    Article  PubMed  CAS  Google Scholar 

  14. Howard-Pitney B, Killen JD, Fortmann SP. Quitting chew: results from a randomized trial using nicotine patches. Exp Clin Psychopharmacol 1999 Nov; 7 (4): 362–71

    Article  PubMed  CAS  Google Scholar 

  15. Stotts RC, Roberson PK, Hanna EY, et al. A randomised clinical trial of nicotine patches for treatment of spit tobacco addiction among adolescents. Tob Control 2003 Dec; 12 Suppl. 4: IV11–5

    PubMed  Google Scholar 

  16. Ebbert JO, Severson HH, Croghan IT, et al. A randomized clinical trial of nicotine lozenge for smokeless tobacco use. Nicotine Tob Res 2009 Dec; 11 (12): 1415–23

    Article  PubMed  CAS  Google Scholar 

  17. Boyle RG. Smokeless tobacco cessation with nicotine replacement: a randomized clinical trial. Diss Abstr Int 1992; 54 (3-A): 825

    Google Scholar 

  18. Hatsukami DK, Jensen J, Allen S, et al. Effects of behavioral and pharmacological treatment on smokeless tobacco users. J Consult Clin Psychol 1996 Feb; 64 (1): 153–61

    Article  PubMed  CAS  Google Scholar 

  19. Ebbert JO, Croghan IT, Severson HH, et al. A pilot study of the efficacy of varenicline for the treatment of smokeless tobacco users in midwestern United States. Nicotine Tob Res 2011 Sep; 13 (9): 820–6

    Article  PubMed  CAS  Google Scholar 

  20. Ebbert JO, Edmonds A, Luo X, et al. Smokeless tobacco reduction with the nicotine lozenge and behavioral intervention. Nicotine Tob Res 2010 Aug; 12 (8): 823–7

    Article  PubMed  CAS  Google Scholar 

  21. Pfizer. A study to evaluate the efficacy and safety of varenicline compared to placebo for smoking cessation through reduction [ClinicalTrials.gov identifier NCT01370356]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov/show/NCT01370356 [Accessed 2012 May 25]

  22. Ebbert JO, Croghan IT, North F, et al. A pilot study to assess smokeless tobacco use reduction with varenicline. Nicotine Tob Res 2010 Oct; 12 (10): 1037–40

    Article  PubMed  CAS  Google Scholar 

  23. Ebbert JO, Croghan IT, Sood A, et al. Varenicline and bupropion sustained-release combination therapy for smoking cessation. Nicotine Tob Res 2009 Mar; 11 (3): 234–9

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pharmacological interventions are of limited benefit in helping individuals to reduce their use of smokeless tobacco. Drugs Ther Perspect 28, 12–15 (2012). https://doi.org/10.1007/BF03262127

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03262127

Keywords

Search

Navigation